NYSE:ADCT
ADC Therapeutics SA
ADC Therapeutics SA's revenue grew 14.9% in fiscal 2025 to $81.4M while operating margin rose to −149.3%. Free cash flow was −$141.4M, −173.8% of revenue, and the diluted share count rose 30.8%.Summary generated from ADC Therapeutics SA's SEC filings. Latest annual report filed Mar 10, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$81.4M
Revenue growth+14.9%
Revenue, 5-yr CAGRn/a
Gross margin92.9%
Operating margin−149.3%
Net margin−175.3%
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flow−$141.4M
FCF margin−173.8%
Share count change+30.8%
Financials
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 210 | 70 | 71 | 81 |
| Operating income | −123 | −166 | −131 | −121 |
| Net income | −157 | −240 | −158 | −143 |
| Free cash flow | −139 | −122 | −125 | −141 |
Recent filings
- 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 8-KResults of operations and financial condition
Aug 13, 2026 - 4Insider transaction report
Jul 2, 2026 - 4Insider transaction report
Jul 2, 2026 - 8-KDirector or officer change
Jul 2, 2026 - 8-KRegulation FD disclosure
Jun 24, 2026 - 8-KRegulation FD disclosure
Jun 3, 2026 - 8-KResults of a shareholder vote
Jun 2, 2026